Keck Graduate Institute of Applied Life Sciences
Watson, CA, United States

Keck Graduate Institute is a private graduate school in Claremont, California. Founded in 1997, it is the newest and 7th member of the Claremont Consortium. It offers 5 graduate degree programs in a range disciplines focusing in the life science industry. KGI programs are organized into two professional schools, the School of Applied Life Science and School of Pharmacy . KGI also offers a four-year undergraduate program, the Minerva Schools at KGI, in partnership with the Minerva Project. Wikipedia.

Time filter
Source Type

-- Molly B. Schmid, Ph.D., consultant for TriTech Small Business Development Center (SBDC), has been inducted into the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE). She was nominated, reviewed, and elected by peers and members of the College of Fellows for "outstanding contributions to research, translational development of novel products in start-up companies and teaching of entrepreneurship and business."AIMBE is the authoritative voice and advocate for the value of medical and biological engineering to society. It is an organization of leaders in medical and biological engineering, consisting of academic, industrial, professional society councils and elected fellows.Dr. Schmid also is a member of the Inland Empire network of the Tech Coast Angels. She has specific expertise in early stage biotechnology companies, stemming from her own roles in scientific management, project leadership, and business development in three biotechnology companies.Her career has been about equally split between academia and industry. She was an assistant professor of Molecular Biology at Princeton University, and was also a professor and entrepreneur-in-residence at Keck Graduate Institute of Applied Life Sciences in Claremont Calif., where she taught courses in drug discovery and entrepreneurship. Prior to KGI, she was senior vice president of Preclinical Programs at Affinium Pharmaceuticals in Toronto, and held leadership positions at Genencor International and Microcide Pharmaceuticals.Dr. Schmid's experiences with these companies included securing venture capital, securing and managing multi-year, multi-million dollar corporate partnerships with Pfizer, Johnson & Johnson, Daiichi Pharmaceuticals, and several other smaller pharmaceutical and biotechnology companies, and playing leadership roles in growing and managing the scientific staff. These three biotech companies provided a wide range of experiences – two companies had IPO's, there were two compounds that entered clinical trials, and two companies ended in Chapter 11 reorganizations. She has nine issued U.S. patents, and several others pending while serving on numerous NSF and NIH grant review panels, and chairing a SBIR grant review panel for several years. She is also a Fellow of the American Academy of Microbiology, a Searle Scholar, and a Damon-Runyon Fellow.About TriTech SBDCTriTech is a Small Business Development Center (SBDC) ( works with high technology high growth firms by offering no cost consulting and training to entrepreneurs and businesses looking for go-to-market strategies that will accelerate the growth of their enterprise. TriTech also provides trainings and workshops on topics that are relevant and valuable to the business community. TriTech has assembled a team of professionals who prepare you for the funding process. TriTech also provides high level referrals to service providers and resources who give companies a competitive advantage. All of TriTech's services are provided at no cost to small businesses.  For further information on TriTech SBDC, please contact Hanah Khaled at 951-571-6378 or hanahkhaled@

Niemz A.,Keck Graduate Institute of Applied Life Sciences | Ferguson T.M.,Claremont Biosolutions, Llc | Boyle D.S.,Program for Appropriate Technology in Health
Trends in Biotechnology | Year: 2011

Nucleic acid testing for infectious diseases at the point of care is beginning to enter clinical practice in developed and developing countries; especially for applications requiring fast turnaround times, and in settings where a centralized laboratory approach faces limitations. Current systems for clinical diagnostic applications are mainly PCR-based, can only be used in hospitals, and are still relatively complex and expensive. Integrating sample preparation with nucleic acid amplification and detection in a cost-effective, robust, and user-friendly format remains challenging. This review describes recent technical advances that might be able to address these limitations, with a focus on isothermal nucleic acid amplification methods. It briefly discusses selected applications related to the diagnosis and management of tuberculosis, HIV, and perinatal and nosocomial infections. © 2011.

Phillips M.I.,Keck Graduate Institute of Applied Life Sciences
Expert Opinion on Orphan Drugs | Year: 2013

For many years the highly profitable pharmaceutical companies had no interest in the rare disease community or its need for orphan product development. The collective rare disease market by definition was small. It did not offer the profits of drugs like antihypertensives with a market of more than 25 million patients. However, nothing stays the same. The blockbuster model that traditionally drove the pharmaceutical industry seems to have lost its relevance. "Big Pharma" has reached out for a new model and found that orphan drugs may be the answer. © Informa UK, Ltd.

Niemz A.,Keck Graduate Institute of Applied Life Sciences | Boyle D.S.,Program for Appropriate Technology in Health
Expert Review of Molecular Diagnostics | Year: 2012

Early diagnosis of tuberculosis (TB) facilitates appropriate treatment initiation and can limit the spread of this highly contagious disease. However, commonly used TB diagnostic methods are slow, often insensitive, cumbersome and inaccessible to most patients in TB endemic countries that lack necessary resources. This review discusses nucleic acid amplification technologies, which are being developed for rapid near patient TB diagnosis, that are in the market or undergoing clinical evaluation. They are based on PCR or isothermal methods and are implemented as manual assays or partially/fully integrated instrument systems, with associated tradeoffs between clinical performance, cost, robustness, quality assurance and usability in remote settings by minimally trained personnel. Unmet needs prevail for the identification of drug-resistant TB and for TB diagnosis in HIV-positive and pediatric patients. © 2012 Expert Reviews Ltd.

Casper S.,Keck Graduate Institute of Applied Life Sciences
Research Policy | Year: 2013

The concept of regional technology spill-overs created by university research is one of the most enduring theories within the economic geography and innovation management fields. This article introduces an alternative perspective on academic commercialization, arguing that the quality of a university's regional environment can significantly impact a university's success in commercializing science. Recent research on university technology transfer stresses the importance of personal contacts between academic and industry scientists in driving commercialization. The social structure of the regional economy in which a university is embedded will strongly influence the density of contacts linking university scientists with individuals in industry, and through doing so, impact the density of networks through which university knowledge can be commercialized. Social network analysis is used to examine the quality of social ties linking industry and university scientists within the San Francisco and Los Angeles California biotechnology industries over the 1980-2005 period. Results support the theory that the existence of strong social networks linking inventors heightens university commercialization output. Despite similar university research endowments, universities in San Francisco have dramatically commercialization outputs than San Francisco, which is correlated with the existence of cohesive inventor networks linking industry and university scientists in this region, but not Los Angeles. Moreover, longitudinal analysis shows that the commercialization output of San Francisco universities increased substantially starting in the early 1990s, the time period in which cohesive inventor networks emerged in the region. © 2013 Elsevier B.V. All rights reserved.

Keck Graduate Institute of Applied Life Sciences | Date: 2013-04-10

A disposable and inexpensive biological diagnostic cartridge for the amplification and detection of nucleic acids includes a configuration having a reaction pouch for amplification which is compressed by a flexible pump pouch for detection of the amplified reaction.

Keck Graduate Institute of Applied Life Sciences | Date: 2014-03-07

In accordance with the invention, isolated nucleic acids, expression methods, host cells, expression vectors, and DNA constructs for producing proteins, and proteins produced using the expression methods are described. More particularly, nucleic acids isolated from Pichia pastoris wherein the nucleic acids have promoter activity are described. The invention also relates to expression methods, host cells, expression vectors, and DNA constructs, for using the Pichia pastoris promoters to produce proteins, and to the proteins produced using the expression methods.

Keck Graduate Institute of Applied Life Sciences | Date: 2013-04-09

A valve has a generally hollow core with one open end and one closed end, and at least one side port in a sidewall of the core. The valve also includes a sleeve that fits over the core and covers the side port(s). The cracking pressure of the valve is tunable by varying the parameters of the sleeve.

Keck Graduate Institute of Applied Life Sciences | Date: 2015-10-23

Compositions and methods including Amodiaquine (AQ) or N-Desethy Amodiaquine (DEAQ) are provided for treating, inhibiting, or preventing cathepsin B dependent pathogens and toxins in a host cell or infected subject. Compositions and methods also include AQ or DEAQ in combination with an antibiotic for more effective clearance of the pathogen and/or toxins.

Keck Graduate Institute of Applied Life Sciences | Date: 2014-01-13

Methods of inhibiting or preventing the proliferation of a fungus and/or a bacteria in a living organism, in water, in air, and/or on surfaces, include administering or providing a therapeutic amount or an effective amount of an antimicrobial composition including Octodrine.

Loading Keck Graduate Institute of Applied Life Sciences collaborators
Loading Keck Graduate Institute of Applied Life Sciences collaborators